701-Redefining Targetable CD70 Expression with HIT T Cells
This paper describe a breakthrough in cancer immunotherapy addressing why CAR T cells often fail to eliminate solid tumors. Research reveals that many tumors appearing to be CD70-negative actually possess ultralow levels of the antigen that are hidden by epigenetic silencing via the protein EZH2. To overcome this, scientists engineered a more sensitive HLA-independent T cell (HIT) receptor capable of detecting these trace amounts of CD70. When combined with specific costimulatory ligands, these HIT T cells successfully achieved complete tumor eradication in models of kidney, ovarian, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.